Premkumar Christadoss M.B.B.S., formed Immune Globe Biotech, LLC in 2014. He is the President, CEO, CSO and Senior Scientist at IGBT. He graduated from Madras Medical College in 1977 and did his postdoctoral training in Immunology at the Mayo Clinic and was awarded the MDA postdoctoral fellowship. He was recruited to UTMB from the University of Vermont in 1990 and promoted to Professor with tenure in 1997.
He has an independent research program related to the cellular and molecular mechanisms of autoimmune myasthenia gravis pathogenesis and the development of specific therapy for this disease. He has published 110 articles, mostly in MG and mostly in peer reviewed high impact journals. He is the primary inventor on three issued patents related to diagnosis and biomarkers and therapy of MG with complement siRNA. He is also the editor of an authoritative published book on MG: Mechanisms of Disease and Immunointervention. He was Honorary Professor at Central South China University and has achieved national and international recognition, as evidenced in part by invitations to speak at Oxford, Karolinsaka and the Weizmann Institute.
Dr. Christadoss has funded his research program at the University of Texas Medical Branch, Galveston, Texas, with awards from the Muscular Dystrophy Association, NIH, pharmaceutical companies, the Association Francaise Centre les Myopathies, MGFA and MGFI. Additionally, he has been successful at obtaining national and international support for his predoctoral and postdoctoral fellows. Dr. Christadoss has received a Fulbright fellowship at Hellenic Pasteur Institute, Greece in 2000. His research program is highly recognized internationally.
Lawry Sower PhD
Dr. Sower is currently the VP Research at Chrysalis BioTherapeutics. She is a trained microbiologist and immunologist with over 20 years of experience in research and the regulated environment. Dr. Sower has implemented a Quality Systems approach in a select agent laboratory. In that environment, she served as the point of contact for several investigators on the Small Animals Models contract with NIAID/NIH. Dr. Sower collected data and wrote all reports for NIAID; initiated conference calls with potential collaborators, negotiated budgets and contracts, and assisted in directing the research within the lab. Dr. Sower was the Director, Research Laboratory Operations and Support at UTMB. In this role, she directed the IACUC, the Post- Approval Monitoring program (PAM) and Research Technology Support. Dr. Sower was responsible for her budget and coordinated meetings with faculty, administrators and upper management. She implemented the emergency preparation program for research laboratories; ran the Presidential Scholars program and served on various institutional committees. In her current role, Dr. Sower directs research for a small drug development startup company implementing a quality system, assuring compliance, enhancing collaboration with the goal of potential licensing of our wound healing peptide.
Jake Lawry DVM
Dr. Jake Lowry is a laboratory animal veterinarian with an interest in translational therapeutics. He earned his Bachelor's of Science in Molecular Biology from Westminster College in 2005. From there he earned a Master's of Science in Pathobiology from the University of Wyoming in 2008 studying developing next generation subunit vaccines for bovine brucellosis. After his first Master's degree he earned a Master's of Public Health in Infectious Disease Epidemiology from the University of Minnesota in 2011 working on brucellosis co-infection models in wild cervids. He then graduated from Colorado State University with his Doctor of Veterinary Medicine in 2012 and began working as a laboratory animal veterinarian. He was elected a Diplomate to the American College of Veterinary Preventative Medicine in 2016.